Vivantes Netzwerk fuer Gesundheit GmbH

The medical center is at the forefront of hematology and oncology research, focusing on innovative treatments for various types of lymphomas and leukemias. The center's work in mantle cell lymphoma and diffuse large B-cell lymphoma is particularly noteworthy, with ongoing trials exploring the efficacy of novel therapeutic combinations.

• Generalized Mantle Cell Lymphoma
• Diffuse Large B-Cell Lymphoma
• Follicular Lymphoma
• Acute Myeloid Leukemia

Through these studies, the center aims to establish new standards of care, improving failure-free survival and progression-free survival for patients.

In the field of neurology, the center is pioneering research into the treatment of epileptic seizures and status epilepticus. The focus is on developing effective therapies for benzodiazepine-resistant seizures in the elderly and exploring new drug candidates for focal-onset seizures.

• Convulsive or Nonconvulsive Status Epilepticus
• Focal-Onset Seizures
• Primary Generalized Tonic-Clonic Seizures

These efforts are crucial in enhancing the quality of life for patients with refractory epilepsy and reducing seizure frequency.

The center is advancing the understanding and treatment of congenital antithrombin deficiency, focusing on the prevention of thrombotic events during surgical procedures. This research is vital for developing safer surgical protocols for patients with this rare condition.

• Congenital Antithrombin Deficiency

By assessing the incidence of thromboembolic events, the center aims to improve patient outcomes and establish new guidelines for perioperative care.

In respiratory medicine, the center is conducting groundbreaking research on idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The focus is on evaluating new treatments that aim to improve lung function and reduce symptoms.

• Idiopathic Pulmonary Fibrosis
• Progressive Pulmonary Fibrosis

These studies are essential for developing therapies that can slow disease progression and enhance the quality of life for patients.

The center is a leader in breast cancer research, particularly in the treatment of hormone receptor-positive and HER2-negative breast cancer. Ongoing trials are exploring the efficacy of novel drug combinations to improve survival rates.

• Hormone Receptor-Positive Breast Cancer
• HER2-Low Breast Cancer

Through these efforts, the center aims to provide more effective treatment options and improve patient outcomes.